| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID1685: Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin's lymphoma |
|
Medicine details |
|
| Medicine name | axicabtagene ciloleucel (Yescarta®) |
| Formulation | intravenous infusion |
| Reference number | 4369 |
| Indication | Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy |
| Company | Gilead Sciences Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/05/2022 |
| NICE guidance | ID1685: Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin's lymphoma |